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ABSTRACT 
Two different approaches for the synthesis of boehmeriasin A are described. The gram scale 
racemic preparation is accompanied by an efficient preparation of both the pure enantiomers using 
the conformationally stable 2-piperidin-2-yl acetaldehyde as starting material. The anti-proliferative 
activity in three cancer cell lines (CEM, HeLa and L1210) and two endothelial cell lines (HMEC-1, 
BAEC) is promising giving activity in the nanomolar range. Topoisomerases and SIRT2 were 
identified as possible biological targets and the experimental data has been supported by docking 
studies. 
INTRODUCTION 
 
Boehmeriasin A (Scheme 1), a phenanthroquinolizidine alkaloid, was isolated from the aqueous 
ethanolic extract of Boehmeria siamensis Craib (Urticaceae) by bioassay-guided fractionation.
1
 In 
vitro tests showed that boehmeriasin A possesses a strong cytotoxic activity, more potent than taxol, 
against 12 cell lines from 6 panels of cancer including breast, kidney, prostate, colon, lung cancer 
and leukemia with GI50 values between 0.2 and 100 ng/mL.  Furthermore, this alkaloid restrains the 
expression of a series of genes related to cell proliferation and cell cycle regulation.
2
 This results in  
G1 phase arrest of the cell cycle and differentiation in the breast cancer cell line MDA-MB-232.
3
 
Consequently, we were attracted by its biological activity, the uncertainty of its  biological 
mechanism and by the features of its structure that show boehmeriasins as possible building blocks 
for further structural modification. In this context we planned a convenient synthesis to both 
enantiomers of boehmeriasin A and the extension of the methodology to a of library of analogues.  
Several synthetic methodologies have been developed for the elaboration of some boehmeriasin A 
congeners (e.g. cryptopleurine and its hydroxy derivatives) in both racemic and optically active 
forms
4-15
  
Herein, we report two synthetic approaches to obtain the racemic mixture and the pure enantiomers 
of boehmeriasin A. Biological evaluation showed high anti-proliferative activity on cancer and 
endothelial cells with topoisomerases and SIRT2 as involved targets. Virtual screening (Hurakan 
tool)
16
 and docking studies support to the experimental results. 
 
RESULTS AND DISCUSSION 
 
Chemistry 
The retrosynthetic plan (Scheme 1) indicates the possibility to first create the phenantrene nucleus 
and then conduct a further cyclization to form the quinolizidine ring (path A) or (path B). This 
would permit the generation of the nitrogen containing bicyclic system in a stereospecific way by 
an intramolecular aldol type reaction followed by an intamolecular arylation reaction.   
Driven by a desire to access both enantiomers of boehmeriasin A we initiated our synthetic efforts 
first though a racemic preparation of the target compound. To this end we pursued the synthesis 
outlined in Scheme 2 which through its simplicity and robustness would allow gram scale quantities 
of the desired natural product to be obtained.  
 
 
Scheme 1. Retrosynthetic Plan 
  
 
 
The synthesis commences with a Perkin reaction between commercially available 4-
methoxybenzaldehyde (3) and 3,4-dimethoxyphenylacetic acid (4). This reaction can be easily 
performed on 100-150 mmol scale. Next a microwave assisted Fischer esterification delivered the 
corresponding ester 5 in quantitative yield through rapid flash heating. In the next step a ferrous 
chloride mediated oxidative biaryl coupling was undertaken. This transformation can be performed 
on multigram scale in an efficient manner, however, the generation of stoichiometric amounts of 
insoluble inorganic by-products requires close reaction monitoring and effective work-up strategies 
in order to achieve a reproducible reaction outcome (see Experimental Section). Reduction of the 
ester functionality of intermediate 6 using LiAlH4 and chlorodehydroxylation of the resulting 
benzylic alcohol 7 with concentrated HCl cleanly affords benzylic chloride 8. This material is 
subjected to nucleophilic substitution with the potassium salt of racemic pipecolic acid furnishing 
the desired adduct 9 without recourse to any protecting group chemistries. In order to prepare the 
pentacyclic scaffold of boehmeriasin A a Friedel-Crafts acylation in neat polyphosphoric acid was 
used. This transformation was found to reliably furnish the desired ketone 10 in good yield, as long 
as the instability of this material under basic conditions is addressed by maintaining the pH during 
the aqueous work-up below 8. Finally removal of the ketone functionality was accomplished in a 
two-step fashion firstly using LiAlH4 followed by dehydroxylation under TFA/triethylsilane 
conditions. In summary, this sequence allowed the preparation of racemic boehmeriasin A in a short 
7 step sequence and in 22 % overall yield. In addition, the feasibility of separating the racemic 
natural product by means of chiral HPLC was evaluated. Pleasingly, it was quickly established that 
for analytical purposes a short chiral HPLC column (AD, 5 cm) can be used in order to achieve 
resolution of the racemic boehmeriasin A (see insert in Scheme 2). Consequently, we feel confident 
that separation of the racemate on a preparative scale using a larger AD column can be 
accomplished, however, before doing so we elected to carry out an asymmetric synthesis of (S)-
/(R)-boehmeriasin A. 
 
Scheme 2. Racemic synthesis of boehmeriasin A and its resolution via chiral HPLC (path A)
a 
 
a
Conditions: : (a) i) Et3N, Ac2O, 120 °C, ii) MeOH, H2SO4, MW, 125°C; (b) DCM, anhydr. FeCl3, r.t.; (c) LiAlH4, 
THF; (d) conc. HCl, DCM, r.t.; (e) pipecolic acid, NaOH, iPrOH, 40 °C; f) PPA, 90 °C; g)  i) LiAlH4, THF, r.t. ii) 
Et3SiH, TFA, DCM, r.t.. 
 
In a second approach we developed an enantioselective synthesis using enatiopure piperidinethanol 
2 as starting material which can be produced at gram scale
17
 and used for target-
17-21
 and diversity-
oriented
22
 synthesis. The aldehyde 11, obtained from oxidation of the corresponding alcohol 2, was 
converted to the secondary alcohol 12 by Grignard addition {4-methoxyphenyl)magnesium 
bromide} (Scheme 3) in high yield (90-92%). DMP (Dess-Martin periodinane) oxidation of alcohol 
12, followed by deprotection of the Boc group (13 → 14) and N-acylation of the amine 14 with the 
easily prepared 2-bromo-4,5-dimethoxyphenylacetic acid
23
 yielded compound 15 in 63% (3 steps) 
(Scheme 3, S-enantiomer shown). An intramolecular aldol-type condensation in the presence of 
KOH furnished the desirable intermediates 16 as mixture of atropoisomers (85%, 1:1 ratio). 
 
Scheme 3. Enantioselective synthesis of boehmeriasin A (path B)
a 
 
 
a
Conditions: (a) (4-methoxyphenyl)magnesium bromide, THF, -78 ºC to r.t.; (b) DMP, r.t., 1 h; (c) TMSCl, MeOH, 0 
ºC to r.t.; (d) 2-bromo-4,5-dimethoxyphenylacetic acid, DIPEA, HATU, THF, r.t., 1 h; (e) KOH, EtOH, reflux, 2 h; (f) 
Pd(OAc)2, K2CO3, 2′-(diphenylphosphino)-N,N′-dimethyl-(1,1′-biphenyl)-2-amine, DMA, reflux, 5 h; (g) LiAlH4, THF, 
reflux, 2 h. 
 
To obtain the phenanthroindolizidine skeleton a palladium catalyzed intramolecular coupling was 
investigated (see Supp. Inf.). The use of Pd(OAc)2 in dimethylacetamide (125 °C for 5 h), in the 
presence of K2CO3  and 2′-(diphenylphosphino)-N,N′-dimethyl-(1,1′-biphenyl)-2-amine as the 
ligand furnished 17 in 60% yield. A final reduction with LiAlH4, completed the synthesis of 
boehmeriasin A. HPLC analysis confirmed the purity of both enantiomers and was in accordance 
with the e.e. of the starting materials (2). 
 
 
 
Biological Evaluation  
 
Anti-proliferative activity. Both enantiomers of boehmeriasin A were evaluated for their anti-
proliferative activity (Table 1) in three cancer cell lines [human lymphoblastic leukemia (CEM), 
human cervical carcinoma (HeLa) and mouse lymphocytic leukemia (L1210) cells] and two 
endothelial cell lines [human microvascular endothelial cells (HMEC-1) and bovine aortic 
endothelial cells (BAEC)]. As a reference compound, we used the vascular-targeting agent 
combretastatin A4P (Ca-4P), which inhibits the proliferation of the tumor cells, and endothelial 
cells with IC50 values around 80 nM and 3 nM, respectively. In accordance with other results 
reported in the literature
1-3, 14
 both enantiomers showed potent cytostatic activity against the 
different tumor cells, with IC50 values in the nanomolar range. Interestingly, (R)-1 proved to be 
significantly more potent than the (S)-enantiomer against HeLa and L1210 cells. Both compounds 
also inhibited the proliferation of endothelial cells, with IC50 values of 23 nM in BAEC and 7 and 
82 nM for the (R)- and (S)-enantiomers in HMEC-1, respectively.  Together, these data confirm the 
inhibitory activity of (R)- and (S)-boehmeriasin A against both tumor and endothelial cells, the (R)-
enantiomer being up to 11-fold more potent than the (S)-enantiomer in selected cell lines. 
 
Table 1. Anti-proliferative activity of (R)- and (S)-boehmeriasin A in comparison with combretastatin A4P. 
 
 
Compound 
Tumor cell lines 
(IC50
[a]
 [nM]) 
Endothelial cell lines 
(IC50
[a]
 [nM]) 
 HeLa CEM L1210 HMEC-1 BAEC 
(R)-1 66 ± 56 185 ± 156 19 ± 10 7.4 ± 1.1 24 ± 13 
(S)-1 182 ± 164 201 ± 127 111 ± 11 82 ± 66 23 ± 6 
CA-4P 79 ± 3 95 ± 6 82 ± 12 2.9 ± 0 3.9 ± 0.1 
a
50% inhibitory concentration. CA-4P: combretastatin A4P. CEM: human lymphoblastic 
leukemia.  HeLa: human cervical carcinoma.  L1210:  mouse lymphocytic leukemia cells. HMEC-
1: human microvascular endothelial cells. BAEC: bovine aortic endothelial cells. 
 
We were attracted by the possibility to identify the biological targets that could justify the anti-
proliferative activity on different cell lines. We wanted to avoid any structural change that could be 
useful for the application of interesting approaches such as surface plasmon resonance, but has the 
drawback to require SAR information to identify the proper alterable region of the molecule.
   
 
Virtual screening. We planned to use virtual screening with the help of Hurakan software
16
 that 
compares the input molecule with the structures present in the reference database using CoMSIA 
fields on a 3D grid. Hurakan uses ChemblDB as a reference database because it contains molecules, 
targets and biological activities. In this way, Hurakan predicts the biological profile of an input 
molecule and, in our case, it predicted 13 proteins for the R-enantiomer and 15 proteins for the S-
enantiomer (see Supporting Information). We were driven by the fact that topoisomerases was 
identified as a possible target for (S)-enantiomer.  
 
Topoisomerases inhibition. Based on our previous efforts in this field,
25-29
 both (R)- and (S)-
boehmeriasin A were tested for their capacity to affect the activity of opoisomerases. 
Figure 1 shows the effect of (R)- and (S)-boehmeriasin A on the relaxation of supercoiled plasmid 
pBR322 DNA, mediated by topoisomerase II. The enzyme relaxes supercoiled DNA (DNA) giving 
rise to a series of topoisomers, representing differently relaxed forms (Topo II). The test compounds 
were assayed at 10, 25 and 50 M concentration, while m-AMSA, taken as reference drug, was 
used at 10 M. Both boehmeriasins A exhibit a comparable and dose-dependent effect on 
enzymatic activity. Indeed, at 10 M both (R)- and (S)-enantiomers are unable to exert a significant 
inhibitory activity, while the topoisomerase-mediated relaxation is completely inhibited at the 
higher concentration taken into account (50 M).  
 
Figure 1. Effect of (R)- and (S)-boehmeriasin A on relaxation of supercoiled pBR322 DNA by human recombinant 
topoisomerase II. m-AMSA was taken as reference. 
 
 
Similar experiments were performed to assay the effect on topoisomerase I relaxation activity as 
well, and the obtained results indicate the occurrence of a higher inhibitory effect compared to that 
obtained on topoisomerase II. Indeed, at 10 concentration both (R)- and (S)-boehmeriasin A 
completely inhibit the relaxation mediated by topoisomerase I (Figure 2). 
 
 
 
 
 
 
Figure 2. Effect of (R)- and (S)-boehmeriasin A on relaxation of supercoiled pBR322 DNA by human recombinant 
topoisomerase I.  
 
 
 
Some anti-proliferative agents, called topoisomerase poisons, interfere with topoisomerase activity 
by stabilizing a biological intermediate, the cleavable complex, into a lethal one. The occurrence of 
the cleavable complex can be demonstrated experimentally by the enzyme-dependent formation of 
linear (topoisomerase II) or nicked (topoisomerase I) DNA from supercoiled DNA. Figure 3 shows 
a cleavable complex assay performed on topoisomerase II in the presence of 100 M of (R)- and 
(S)-boehmeriasin A and 10 M m-AMSA used as reference. The results show that both derivatives 
cannot stabilize the formation of the cleavage complex, although tested at a significantly higher 
concentration compared to that of the reference drug. Otherwise, as expected, m-AMSA, which is a 
well-known topoisomerase II poison, induces the formation of a detectable amount of linear DNA 
(Figure 3).   
 
Figure 3. Effect of (R)- and (S)-boehmeriasin A on the stabilization of covalent DNA-topoisomerase II complex. m-
AMSA was taken as reference. 
 
 
As regards topoisomerase I, the results reported in Figure 4 also show the inability of both (R)- and 
(S)-boehmeriasin A to act as poison at the considered concentration (0.5 µM). On the other hand, 
the topoisomerase I poison camptothecin (CPT), taken as reference, induces in the same 
experimental conditions the occurrence of the band corresponding to nicked DNA (Figure 4). 
 
Figure 4. Effect of (R)- and (S)-boehmeriasin A on the stabilization of covalent DNA-topoisomerase I complex. 
Camptothecin (CPT) was taken as reference. 
 
 
Finally, the ability of (R)- and (S)-boehmeriasin A to interfere with topoisomerase-mediated 
relaxation activity, along with the lack of poisoning effect, suggest that the effect on the enzymatic 
activity could come from the capacity of the compounds to form a molecular complex with DNA. 
 
Sirtuins inhibition. We were driven to study boehmeriasin A against sirtuins because it has some 
structural similarity with known sirtuin inhibitors.
30
 Both enantiomers were screened in vitro 
against SIRT1 and SIRT2 at 200 µM concentration (Table 2). For SIRT1 (R)- and (S)-boehmeriasin  
A showed no inhibition. Interestingly, for SIRT2 (R)-boehmeriasin  A  gave ~65 % inhibition, 
whereas  (S)-boehmeriasin  A  gave only 41% inhibition.   
 
Table 2. Evaluation of (R)- and (S)-boehmeriasin A against SIRT1 and SIRT2. 
Compound SIRT1 SIRT2 
(R)-1 12 ± 1.4 65 ± 1.6 
(S)-1 10 ± 4.2 41 ± 0.56 
Control 100 ± 0.06 100 ± 0.26 
 
Docking Studies. To gain better insight of the interactions between boehmeriasin A with 
topoisomerases and sirtuins, molecular dockings studies were carried out.   
Topoisomerases – Boehmeriasin A has a polycyclic structure and contains a phenantrene moiety 
that suggest it could act as a DNA intercalant, thus inhibiting topoisomerase action.  The structure 
of topoisomerase I/DNA complex has been crystallised in complex with camptothecin, while  
topoisomerase II-beta/DNA has been obtained in complex with amsacrine, both well-known 
topoisomerase inhibitors, which are bound into the enzyme mediated DNA cleavage site 
intercalating between DNA base pairs. The pockets formed by camptothecin and amsacrine upon 
binding to DNA in complex with topoisomerase I and II, respectively have been chosen as the 
putative binding sites of boehmeriasin A (see the Experimental Section). Both R and S enantiomers 
have been docked. Docking simulations on topoisomerase I showed that both boehmerasin 
enantiomers display good binding affinity to the target. Cluster analysis showed two major clusters,  
comprising 50 % and 36% of the docked structures of the S enantiomer (Figure 5), and two minor 
clusters. All these clusters are almost isoenergetic, with binding energy around -14 kcal/mol. The R 
enantiomer, on the other hand, displayed one dominant cluster, comprising 98% of the docking 
decoys (Figure 6). Cluster analysis of the docking results on the topoisomerase II showed only one 
cluster for the S enantiomer, with the  phenantrene moiety stacked between the DNA bases (Figure 
7). The binding energy of the best fit structure is -16.52 kcal/mol.  The R enantiomer showed two 
distinct clusters: the principal one populated by 66% of the docked structures and the secondary one 
containing 34% of the docked structures (Figure 8). The binding energy of the best fit structures of 
the two aforementioned clusters are -15.63 and  -15.37 kcal/mol, respectively. Generally, the energy 
difference between clusters of docked structures of the same enantiomer, as well as the binding 
energy difference between S and R enantiomers bound to the same target is not significant in both 
targets. This fact can be ascribed to the identical nature of the stacking interactions observed in all 
the docked structures. It’s worth noting that the error associated to the Autodock empirical score 
function is estimated around ±2 kcal/mol, making smaller differences in energy hardly significant 
and interpretable.
31
 A slight preference toward  topoisomerase II can, on the other hand, be inferred 
on the basis of the docking results. It’s worth noting that in all the docked conformations both S and 
R enantiomers of boehmeriasin A do not display any significant contact with either one of the 
topoisomerase isoforms that have been tested, but seem to mainly interact with the DNA strand 
through stacking interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Docked structure of (S)-boehmeriasin A. The best fit structure of the principal cluster is depicted in orange, 
while the best fit structure of secondary cluster is green. Boehmerasin is intercalated between DNA bases of the nucleic 
acid double helix complexed with topoisomerase I. 
 
 
 
Figure 6. Docked structure of  (R) boehmeriasin A (blue molecule). 
 
 
 
 
Figure 7. Docked structure of (S)-boehmeriasin A (orange molecule). The phenantrene moiety is intercalated between 
base pairs of the  DNA in complex with topoisomerase II. 
 
 
 
Figure 8. Docked structure of (R)-boehmeriasin A. The best fit structure of the principal cluster is depicted in red, while 
the best fit structure of secondary cluster is in blue. A very similar binding energy corresponds to these structurally 
different poses (see text). 
 
 
Sirtuins - In SIRT1, both enantiomers of boehmeriasin A were docked into the place of the 
nicotinamide-moiety (so called C-pocket in sirtuins) showing π-interactions with His363 or Phe273 
but they were not able to have proper orientation in the binding pocket (Figure 9). As for SIRT2, 
(R)-boehmeriasin A also docked into C-pocket having an interaction of the phenyl-ring with Ile169 
and showed good complementary with the binding site. Whereas (S)-boehmeriasin A had no 
interactions with SIRT2, but showed also complementary binding (Figures 10 and 11). Based on the 
modeling there was no clear difference in the putative binding modes of the enantiomers. 
 
Figure 9. (R)-Boehmeriasin A (green) in the putative binding site of SIRT2. NAD+ (black) and Ex-527(purple) is also 
presented based on their position in SIRT1. 
 
 
 
 
 
 
Figure 10. (R)-boehmeriasin A interacts with Ile169 in SIRT2. Boehmeriasin A doesn’t orientate properly in the 
putative binding site of SIRT1. 
 
CONCLUSION 
We described two different approaches for the synthesis of boehmeriasin A which in spite of being  
strategically based on previous reported preparations present some novelties that result in efficacy, 
simplicity even for large-scale production. The high anti-proliferative activity in three endothelial 
and two cancer cell lines  was described. The biological evaluation accompanied by virtual 
screening and docking studies permitted to identify the interaction with DNA and SIRT2 as 
biological mechanisms that justify their activity. These results offer new suggestions for the design 
and practical synthesis of new topoisomerase and SIRT-2 inhibitors based on boehemeriasin A 
scaffold. 
 
 
EXPERIMENTAL SECTION 
 
General procedures.  
 
All reactions were carried out in oven-dried glassware and dry solvents under nitrogen 
atmosphere. Unless otherwise stated, all solvents were purchased from Fisher Scientific and Sigma 
Aldrich and used without further purification. Substrates and reagents were purchased from Alfa 
Aesar or Sigma Aldrich and used as received. Thin layer chromatography (TLC) was performed on 
Merck precoated 60F254 plates. Reactions were monitored by TLC on silica gel, with detection by 
UV light (254 nm) or by a solution of KMnO4 with heating. Flash chromatography was performed 
using silica gel (240-400 mesh, Merck). All tested compounds possessed a purity of > 98% 
confirmed via elemental analyses (CHN) in Perkin Elmer 2400 instrument. Optical rotation was 
measured on a JAS.CO P-1030 instrument. 
1
H-NMR spectra were recorded on either Bruker DRX-
400 or Bruker Avance-400 or Varian VNMRS-700 instruments and are reported relative to residual 
CHCl3 (δ 7.26 ppm) or DMSO (δ 2.50 ppm). 
13
C-NMR spectra were recorded on the same 
instruments (100 MHz or 175 MHz) and are reported relative to CDCl3 (δ 77.16 ppm) or d6-DMSO 
(δ 39.52 ppm). Chemical shifts (δ) for proton and carbon resonances are quoted in parts per million 
(ppm) relative to tetramethylsilane (TMS), which was used as an internal standard. COSY, HSQC, 
HMBC and NOESY experiments were used in the structural assignment. Low and high resolution 
mass spectrometry was performed using the indicated techniques on either Waters LCT Premier XE 
or Waters TQD instruments equipped with Acquity UPLC and a lock-mass electrospray ion source. 
EI mass spectra were recorded at an ionizing voltage of 6Kev on a VG 70-70 EQ. Melting ranges 
were recorded on an Optimelt automated melting point system and are uncorrected operating at a 
heating rate of 1 °C/min.  
 
(E)-Methyl 2-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)acrylate (5). 4-Methoxybenzaldehyde 
(3) (13.6 g, 100 mmol) and 3,4-dimethoxyphenylacetic acid (4) (19.6 g, 100 mmol) were dissolved 
in a mixture of triethylamine (10 mL) and acetic anhydride (20 mL) and heated at 120 °C for 30 h. 
After the reaction mixture was cooled to room temperature ethyl acetate (150 mL) was added 
leading to precipitation of a yellow solid. After filtration and drying this material was charged into 
20 mL microwave vessels (~4 g each), filled with 7 mL methanol and 0.1 mL conc. sulfuric acid 
and sealed with the appropriate cap. Each of these samples was heated in a Biotage Microwave 
Synthesizer for 90 min at 125 °C. Upon cooling to rt the desired ester product precipitated as pale 
yellow solid and was isolated by filtration. Yield (over 2 steps) 70-75 % (23-25g); mp 106.7-107.9 
°C (MeOH). 
1
H NMR (CDCl3, 400 MHz) δ: 7.77 (1H, s), 7.02 (2H, d, J = 8.8 Hz), 6.89 (1H, d, J = 
8.0 Hz), 6.78 (1H, dd, J = 8.0 Hz J = 1.6 Hz), 6.73 (1H, d, J = 1.6 Hz), 6.69 (2H, d, J = 8.8 Hz), 
3.92 (3H, s), 3.80 (3H, s), 3.78 (3H, s), 3.75 (3H, s). 
13
C NMR (CDCl3, 100 MHz) δ: 168.7, 160.3, 
149.1, 148.6, 140.2, 132.4, 129.6, 128.6, 127.3, 122.1, 113.7, 112.8, 111.4, 55.88, 55.81, 55.22, 
52.29. ESI-MS: 351.8 [M+Na]
+
. HR-MS: calculated for C19H21O5 329.1389, found 329.1393. 
 
Methyl 3,6,7-trimethoxyphenanthrene-9-carboxylate (6). (E)-methyl 2-(3,4-dimethoxyphenyl)-
3-(4’’-methoxyphenyl)acrylate (5) (4 g, 12.2 mmol) was dissolved in DCM (40 mL) at rt. To this 
solution anhydrous FeCl3 (5 g, 31 mmol) was added portionwise. The resulting reaction mixture 
was stirred at ambient temperature for 3 h after which more anhydrous FeCl3 (1 g, 6 mmol) was 
added. After a total reaction time of 5 h complete consumption of substrate was achieved 
(monitored by 
1
H NMR). Methanol (~30 mL) was added to this crude mixture resulting in a 
homogeneous red-brownish solution, which was subsequently extracted with DCM/water giving the 
desired phenanthrene product as dark brown foam after evaporation of the solvents. Filtration of the 
dried organic layer over a plug of silica gel (10 g) prior to solvent removal yields the desired 
product as light brown foam. At this scale the isolated yield commonly varied from 60-75% (>90% 
purity). 
1
H NMR (CDCl3, 400 MHz) δ: 8.64 (1H, s), 8.43 (1H, s), 7.85 (1H, s), 7.84 (1H, d, J = 8.8 
Hz), 7.79 (1H, d, J = 2.4 Hz), 7.20 (1H, dd, J = 8.8 Hz J = 2.4 Hz), 4.10 (3H, s), 4.08 (3H, s), 4.02 
(3H, s), 4.01 (3H, s). 
13
C NMR (CDCl3, 100 MHz) δ: 168.2, 160.2, 149.9, 148.9, 133.4, 131.8, 
131.3, 125.2, 125.0, 124.2, 121.6, 116.0, 106.9, 103.7, 103.2, 55.90, 55.87, 55.53, 52.03. ESI-MS: 
327.0 [M+H]
+
. HR-MS: calculated for C19H19O5 327.1232, found 327.1240. 
 
(3,6,7)-Trimethoxyphenanthren-9-yl)-methanol (7). Methyl 3,6,7-trimethoxyphenanthrene-9-
carboxylate (6) (3.26 g, 10.0 mmol) was dissolved in THF (20 mL) and cooled to 0 °C. To this 
vigorously stirred solution, LiAlH4 (880 mg, 25 mmol) was added in small portions over a period of 
10 min. After 30 min the ice bath was removed allowing the reaction mixture to warm to rt where it 
was maintained for 2 h. Upon quenching of the reaction mixture with sat. NH4Cl (2 mL) a greyish 
slurry was obtained which was filtered over a plug of silica (eluent DCM). The desired reduction 
product was obtained after removal of the volatiles as a pale yellow amorphous solid. Yield 95% 
(2.82 g). 
1
H NMR (CDCl3, 700 MHz) δ: 7.79 (1H, s), 7.73 (1H, d, J = 2.1 Hz), 7.69 (1H, d, J = 9.1 
Hz), 7.51 (1H, s), 7.45 (1H, s), 7.15 (1H, dd, J = 9.1 Hz J = 1.2 Hz), 5.01 (2H, s), 4.06 (3H, s), 4.01 
(3H, s), 3.99 (3H, s), 1.92 (1H, br. s). 
13
C NMR (CDCl3, 175 MHz) δ: 158.3, 149.3, 148.7, 131.3, 
131.1, 130.1, 125.7, 125.5, 124.8, 124.4, 115.4, 104.8, 103.9, 103.7, 64.59, 55.91, 55.86, 55.47. 
ESI-MS: 281.0 [M-OH]
+
. HR-MS: calculated for C18H17O3 (M-OH) 281.1178, found 281.1186. 
 
10-(Chloromethyl)-2,3,6-trimethoxyphenanthrene (8). To a vigorously stirred solution of (3,6,7)-
trimethoxyphenanthren-9-yl)-methanol (7) (3.0 g, 10 mmol, in DCM) was added conc. HCl (37 %, 
5 mL) changing the color of the initial pale yellow solution to dark brown. After 2 h at rt the 
reaction is directly extracted (DCM/H2O) giving the title compound 8 as brown solid after removal 
of the solvent.  Yield 98% (3.1 g). 
1
H NMR (CDCl3, 400 MHz) δ: 7.76 (1H, s), 7.70 (1H, d, J = 2.4 
Hz), 7.66 (1H, d, J = 8.4 Hz), 7.51 (1H, s), 7.40 (1H, s), 7.14 (1H, dd, J = 8.4 Hz J = 2.4 Hz), 4.92 
(2H, s), 4.05 (3H, s), 4.04 (3H, s), 3.96 (3H, s). 
13
C NMR (CDCl3, 100 MHz) δ: 158.8, 149.4, 148.9, 
131.7, 130.4, 127.9, 126.8, 125.2, 125.1, 125.0, 115.6, 104.7, 103.8, 55.96, 55.91, 55.47, 46.11. 
ESI-MS (ASAP): 316.1 [radical cation]. HR-MS: calculated for C18H18O3Cl 317.0944, found 
317.0931. 
 
Potassium 1-[(3,6,7-trimethoxyphenanthren-9-yl)methyl]piperidine-2-carboxylate (9). A 
suspension containing rac-pipecolic acid (750 mg, 5.8 mmol) and potassium hydroxide (1.0 g, 17.9 
mmol) in isopropanol (6 mL) is stirred at r.t. for 30 min. To this mixture 10-(chloromethyl)-2,3,6-
trimethoxyphenanthrene (8) (1.6 g, 5 mmol) is added portionwise over 30 min creating a beige 
slurry. This mixture is stirred at 40 °C for 14 h before cooling to rt. Filtration and washing of this 
crude material, with a minimal amount of cold isopropanol (3 mL), yields the title compound 9 as 
beige solid which is used in the subsequent step without further purification. Yield 87% (1.9 g > 90 
% pure). 
1
H NMR (d6-DMSO, 700 MHz) δ: 8.81 (1H, s), 7.94 (2H, br. s), 7.73 (1H, d, J = 8.4 Hz), 
7.39 (1H, s), 7.11 (1H, dd, J = 8.4 Hz J = 2.8 Hz), 4.58 (1H, d, J = 12.6 Hz), 3.97 (3H, s), 3.96 (3H, 
s), 3.92 (3H, s), 3.03 (1H, d, J = 12.6 Hz), 2.54 (1H, m), 2.49 (1H, m), 1.68-1.73 (2H, m), 1.50-1.58 
(2H, m), 1.25-1.30 (1H, m), 1.10-1.18 (2H, m). 
13
C NMR (d6-DMSO, 175 MHz) δ: 177.7, 158.1, 
149.2, 149.0, 131.3, 131.0, 130.0, 127.8, 126.0, 125.5, 124.5, 115.9, 109.6, 104.2, 103.8, 71.8, 60.5, 
56.68, 56.11, 55.88, 51.41, 30.87, 25.97, 24.63. 
 
3,6,7-Trimethoxy-12,13,14,14a-tetrahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinolin-15(11H)-
one (10). Potassium 1-((3,6,7-trimethoxyphenanthren-9-yl)methyl)piperidine-2-carboxylate (9) 
(900 mg, 2.0 mmol) is added to polyphosphoric acid (~3 g) and stirred at 90 
o
C for 4-5 h. Within 30 
min a thick black solution is obtained which is maintained at this temperature until full conversion 
of the substrate is obtained (monitored by LC-MS). The reaction mixture is then cooled to rt and 
carefully quenched by addition of methanol not allowing the temperature to rise above ~40 °C (ice-
bath). The resulting solution is then neutralized by careful addition of a saturated solution of 
potassium carbonate. Extractive work-up of this material with DCM/H2O gives a crude product 
which can be purified further by column chromatography (15 % EtOAc/Hex) providing the title 
compound 10 as a pale yellow solid. Yield 70%. 
1
H NMR (CDCl3, 700 MHz) δ: 9.26 (1H, d, J = 
9.8 Hz), 7.24 (1H, s), 7.72 (1H, d, J = 1.4 Hz), 7.22 (1H, dd, J = 9.8 Hz J = 1.4 Hz), 7.11 (1H, s), 
4.36 (1H, d, J = 15.4 Hz), 4.07 (3H, s), 4.01 (3H, s), 3.97 (3H, s), 3.65 (1H, d, J = 15.4 Hz), 3.19 
(1H, d, J = 10.5 Hz), 2.77 (1H, d, J = 10.5 Hz), 2.47 (1H, d, J = 13.3 Hz), 2.40 (1H, t, J = 13.3 Hz), 
1.96 (1H, d, J = 13.3 Hz), 1.70-1.77 (1H, m), 1.66 (1H, tq, J = 13.3 Hz J = 2.8 Hz), 1.60 (1H, q, J = 
13.3 Hz), 1.45 (1H, tq, J = 13.3 Hz J = 2.8 Hz). 
13
C NMR (CDCl3, 175 MHz) δ: 197.3, 157.8, 
151.0, 149.5, 139.3, 130.9, 129.3, 127.3, 123.1, 123.0, 122.7, 115.6, 104.3, 104.3, 103.7, 68.92, 
55.99, 55.96, 55.89, 55.34, 54.85, 27.38, 24.98, 23.97. ESI-MS: 392.0 [M+H]
+
. HR-MS: calculated 
for C24H26O4N 392.1861, found 392.1855. 
 
1-(4-Methoxyphenyl)-2-(1-tert-butoxycarbonylpiperidin-2-yl)ethanol (12). To a solution of 
aldehyde 11 (0.34g, 1.5 mmol) in THF (13 mL) at −78 ºC, (4-methoxyphenyl)magnesium bromide 
(6 mL, 3 mmol) was added, and the new solution was stirred for 10 min at −78 ºC and then 
overnight at rt. After the completion of the reaction, the solvent was evaporated in vacuum, sat. 
NH4Cl was added and the aqueous layer was extracted 3 times with EtOAc. The combined organic 
layers were washed with water and brine, dried with Na2SO4, filtered and evaporated. The residue 
was purified by flash column chromatography (Hex/EtOAc 7:3) to provide the two diastereomer 
alcohols 12 as oils. 12a (R-COH) and 12b (S-COH): Yield 92-95%; Rf = 0.39 (Hex/EtOAc, 7:3); 
12a (R-COH):  = + 35.9 (c = 0.90 in CHCl3), HR-MS: calculated for C19H30NO4 336.2175, 
found 336.2156; 12b (S-COH):  = − 36.6 (c = 0.92 in CHCl3), HR-MS found 336.2179. 
1
H 
NMR (CDCl3, 400 MHz): δ = 7.32 (2H, d, J = 8.4 Hz), 6.90 (2H, d, J = 8.4 Hz), 4.61 (1H, m), 4.41 
(1H, m), 4.04 (1H, m), 3.82 (3H, s), 2.80 (1H, t, J = 11.6 Hz), 2.20 (1H, td, J = 14.0 Hz J = 2.0 Hz), 
1.78 – 1.47 (8H, m), 1.52 (9H, s). 13C NMR (CDCl3, 100 MHz): δ = 159.0, 155.6, 136.9, 127.5, 
114.4, 81.08, 70.16, 55.99, 47.36, 40.88, 40.25, 29.97, 29.13, 26.20, 19.87. 12a (S-COH) and 12b 
(R-COH): oils; yields 92-95 %; Rf = 0.17 (Hex/EtOAc, 7:3); 12a (S-COH):  = + 71.9 (c = 1.06 
in CHCl3), HR-MS: found 336.2160; 12b (R-COH):  = − 73.3 (c = 0.98 in CHCl3), HR-MS: 
found 336.2158. 
1
H NMR (CDCl3, 400 MHz): δ = 7.32 (2H, d, J = 8.4 Hz), 6.89 (2H, d, J = 8.4 
Hz), 4.71 (1H, m), 4.38 (1H, m), 3.94 (1H, m), 3.82 (3H, s), 2.82 (1H, td, J = 13.2 Hz J = 1.6 Hz), 
2.12 (1H, dt, J = 14.4 Hz J = 6.8 Hz), 1.85 (1H, dt, J = 14.4 Hz J = 5.6 Hz), 1.62 – 1.51 (6H, m), 
1.48 (9H, s), 1.43 – 1.40 (1H, m). 13C NMR (CDCl3, 100 MHz): δ = 159.6, 156.2, 137.6, 127.7, 
114.4, 80.41, 73.03, 55.98, 49.32, 40.86, 40.19, 30.39, 29.17, 25.96, 19.80.  
 
1-(4-Methoxyphenyl)-2-(1-tert-butoxycarbonylpiperidin-2-yl)ethanone (13). To a solution of 
alcohol 12 (0.22 g, 0.65 mmol) in DCM (8.4 mL), Dess-Martin periodinane (0.34 g, 0.78 mmol) 
was added and the new mixture was stirred for 1 h at rt. After the completion of the reaction, the 
solvent was evaporated in vacuum, 10% K2CO3 was added and the aqueous layer was extracted 3 
times with EtOAc. The combined organic layers were washed with water and brine, dried with 
Na2SO4, filtered and evaporated. The residue was purified by flash column chromatography 
(Hex/EtOAc 7:3) to provide ketone 13 as oil. Yield 83%; Rf = 0.38 (Hex/EtOAc, 7:3); 13a:  = 
− 34.2 (c = 0.95 in CHCl3), HR-MS: calculated for C19H28NO4 334.2018, found 334.2009; 13b: 
 = + 35.6 (c = 1.00 in CHCl3), HR-MS: found 334.2006. 
1
H NMR (CDCl3, 400 MHz): δ = 
8.00 (2H, d, J = 8.8 Hz), 6.96 (2H, d, J = 8.8 Hz), 4.82 (1H, m), 4.05 (1H, m), 3.89 (3H, s), 3.18 
(1H, dd, J = 14.0 Hz J = 6.4 Hz), 3.12 (1H, dd, J = 14.0 Hz J = 6.4 Hz), 2.90 (1H, td, J = 13.0 Hz J 
= 2.3 Hz), 1.64 (5H, m), 1.41 (10H, s). 
13
C NMR (CDCl3, 100 MHz): δ = 197.0, 163.6, 154.8, 
130.6, 130.1, 113.8, 79.57, 55.49, 48.44, 39.44, 38.99, 28.38, 28.13, 25.34, 18.90.  
 
1-(4-Methoxyphenyl)-2-(piperidin-2-yl)ethanone hydrochloride (14). To a cooled solution at 0 
ºC of ketone 13 (0.31 g, 0.94 mmol) in MeOH (7.5 mL), TMSCl (0.59 mL, 5.7 mmol) was added 
and the new solution was stirred overnight at rt. After the completion of the reaction, the solvent 
was evaporated in vacuum, to provide ketone 14 as oil. Yield 95%; 14a:  = + 17.5 (c = 1.14 in 
CHCl3); 14b:  = − 18.5 (c = 1.25 in CHCl3) for (S)-14. 
1
H NMR (CDCl3, 400 MHz): δ = 9.73 
(1H, s), 9.30 (1H, s), 7.92 (2H, d, J = 8.0 Hz), 6.86 (2H, d, J = 8.0 Hz), 3.84 (3H, s), 3.78 – 3.72 
(1H, m), 3.70 – 3.64 (1H, m), 3.55 – 3.47 (2H, m), 2.97 – 2.91 (1H, m), 2.00 – 1.80 (5H, m), 1.58 – 
1.50 (1H, m). 
13
C NMR (CDCl3, 100 MHz): δ = 195.7, 164.7, 131.4, 129.7, 114.6, 56.21, 54.67, 
45.82, 41.62, 29.12, 23.08, 22.82.  
 
2-(2-Bromo-4,5-dimethoxyphenyl)-1-(2-(2-(4-methoxyphenyl)-2-oxoethyl)piperidin-1-
yl)ethanone (15). To a solution of 2-bromo-4,5-dimethoxyphenylacetic acid (0.25 g, 0.90 mmol) in 
THF (23 mL), HATU (0.39 g, 0.99 mmol) and DIPEA (0.31 mL, 1.8 mmol) were added and the 
new mixture was stirred for 30 min at rt. Then, the solution was cooled at 0 ºC and a solution of 
compound 14 (0.24 g, 0.90 mmol) in THF (12 mL) and DIPEA (200 µL) was added and the new 
solution was stirred for 1 h at rt. After the completion of the reaction, the solvent was evaporated in 
vacuum, sat. NH4Cl was added and the aqueous layer was extracted 3 times with DCM. The 
combined organic layers were washed with water and brine, dried with Na2SO4, filtered and 
evaporated. The residue was purified by flash column chromatography (Hex/EtOAc 3:7) to provide 
compound 15 as oil. Yield 80%; Rf = 0.25 (Hex/EtOAc, 3:7); 15a:  = − 1.2 (c = 0.82 in 
CHCl3), HR-MS: calculated for C24H29BrNO5 490.1229, found 490.1215; 15b:  = + 1.3 (c = 
0.86 in CHCl3), HR-MS: found 490.1210. 
1
H NMR (CDCl3, 400 MHz, amide rotamers 1:1): 
rotamer a δ = 8.05 (2H, d, J = 8.8 Hz), 7.03 (1H, s), 6.97 (2H, d, J = 8.8 Hz), 6.83 (1H, s), 5.33 – 
5.28 (1H, m), 4.00 (1H, d, J = 16.0 Hz), 3.90 (3H, s), 3.87 (3H, s), 3.85 (3H, s), 3.78 – 3.72 (2H, 
m), 3.26 (2H, d, J = 6.8 Hz), 3.23 – 3.20 (1H, m), 1.78 – 1.56 (5H, m), 1.46 – 1.30 (1H, m) and 
rotamer b δ = 7.93 (2H, d, J = 8.8 Hz), 6.96 (1H, s), 6.95 (2H, d, J = 8.8 Hz), 6.83 (1H, s), 4.78 – 
4.74 (1H, m), 4.67 – 4.64 (1H, m), 3.87 (3H, s), 3.85 (3H, s), 3.81 (3H, s), 3.78 – 3.72 (2H, m), 3.18 
– 3.09 (2H, m), 2.70 (1H, td, J = 13.0 Hz J = 2.4 Hz), 1.78 – 1.56 (5H, m), 1.46 – 1.30 (1H, m). 13C 
NMR (CDCl3, 100 MHz): rotamer a δ = 197.5, 170.4, 164.5, 149.2, 149.0, 131.5, 130.5, 128.1, 
116.0, 115.3, 114.6, 114.0, 56.74, 56.21, 47.40, 42.72, 41.55, 39.65, 29.99, 26.29, 20.00 and 
rotamer b δ = 196.4, 170.1, 164.3, 149.2, 149.0, 131.0, 130.3, 127.7, 116.0, 115.0, 114.6, 113.5, 
56.74, 56.14, 50.36, 41.13, 39.25, 38.32, 27.96, 26.16, 19.35.  
 
3-(2-Bromo-4,5-dimethoxyphenyl)-2-(4-methoxyphenyl)-1,6,7,8,9,9a-hexahydroquinolizin-4-
one (16). A solution of compound 15 (0.37 g, 0.76 mmol) in 5% ethanolic KOH (15.8 mL) was 
refluxed for 2 h. After the completion of the reaction, the solvent was evaporated in vacuum, sat. 
NH4Cl was added and the aqueous layer was extracted 3 times with DCM. The combined organic 
layers were washed with water and brine, dried with Na2SO4, filtered and evaporated. The residue 
was purified by flash column chromatography (Hex/EtOAc 4:6) to provide atropisomer compounds 
16 as oils. Yield 85%; 16a (mode 1): Rf = 0.35 (Hex/EtOAc, 4:6);  = + 57.6 (c = 0.89 in 
CHCl3); HR-MS: calculated for C24H27BrNO4  472.1123, found 472.1110. 16b (mode 1):  = − 
58.4 (c = 0.62 in CHCl3); HR-MS: found 472.1109. 
1
H NMR (CDCl3, 400 MHz): δ = 7.01 (2H, d, J 
= 8.4 Hz), 7.00 (1H, s), 6.70 (2H, d, J = 8.4 Hz), 6.46 (1H, s), 4.56 (1H, br. d, J = 13.6 Hz), 3.86 
(3H, s), 3.76 (3H, s), 3.68 (1H, m), 3.65 (3H, s), 2.86 – 2.69 (3H, m), 1.95 – 1.84 (3H, m), 1.58 – 
1.44 (3H, m). 
13
C NMR (CDCl3, 100 MHz): δ = 166.8, 159.8, 149.3, 148.7, 146.3, 132.2, 131.3, 
131.2, 129.6, 116.1, 115.6, 115.5, 114.0, 56.74, 56.58, 55.82, 54.11, 43.46, 38.30, 34.06, 25.37, 
23.97. EI-MS 392: [M-Br]. 16a (mode 2): Rf = 0.23 (Hex/EtOAc, 4:6);  = − 39.2 (c = 1.09 in 
CHCl3); HR-MS: found 472.1113. 16b (mode 2):  = + 40.4 (c = 1.10 in CHCl3); HR-MS: 
found 472.1034. 
1
H NMR (CDCl3, 400 MHz): δ = 7.04 (2H, d, J = 8.8 Hz), 6.99 (1H, s), 6.71 (2H, 
d, J = 8.8 Hz), 6.50 (1H, s), 4.62 (1H, br. d, J = 13.6 Hz), 3.85 (3H, s), 3.76 (3H, s), 3.70 (3H, s), 
3.67 – 3.60 (1H, m), 3.09 (1H, dd, J = 17.2 Hz J = 6.4 Hz), 2.69 – 2.63 (2H, m), 1.97 – 1.92 (1H, 
m), 1.89 – 1.82 (1H, m), 1.76 – 1.73 (2H, m), 1.70 – 1.59 (2H, m). 13C NMR (CDCl3, 100 MHz): δ 
= 166.1, 159.2, 148.6, 148.0, 145.7, 131.9, 130.5, 130.4, 128.9, 115.8, 115.2, 115.0, 113.4, 56.08, 
55.95, 55.15, 53.46, 44.64, 36.09, 32.54, 25.10, 24.42.  
 
3,6,7-Trimethoxy-11,12,13,14,14a,15-hexahydro-9H-phenanthro[9,10-b]quinolizin-9-one (17). 
To a solution of compound 16 (0.12 g, 0.24 mmol) in DMA (5.3 mL), Pd(OAc)2 (13 mg, 0.058 
mmol), 2′-(diphenylphosphino)-N,N′-dimethyl-(1,1′-biphenyl)-2-amine (28 mg, 0.072 mmol) and 
K2CO3 (0.066 g, 0.48 mmol) were added and the new mixture was heated at 125 ºC for 5 h. After 
the completion of the reaction, H2O was added and the aqueous layer was extracted 3 times with 
EtOAc. The combined organic layers were washed with water and brine, dried with Na2SO4, 
filtered and evaporated. The residue was purified by flash column chromatography (Hex/EtOAc 
4:6) to provide compound 17 as oil. Yield 60%; Rf = 0.46 (Hex/EtOAc, 3:7); 17a:  = − 108.4 
(c = 0.44 in CHCl3), HR-MS calculated for C24H26NO4 392.1861, found 392.1850; 17b:  = + 
110.2 (c = 0.65 in CHCl3), HR-MS found 392.1847. 
1
H NMR (CDCl3, 400 MHz): δ = 9.41 (1H, s), 
8.01 (1H, d, J = 8.8 Hz), 7.88 (1H, d, J = 3.2 Hz), 7.87 (1H, s), 7.23 (1H, dd, J = 9.2 Hz J = 2.4 Hz), 
4.74 (1H, br. d, J = 11.6 Hz), 4.12 (6H, s), 4.05 (3H, s), 3.64 – 3.56 (1H, m), 3.52 (1H, dd, J = 16.4 
Hz J = 4.8 Hz), 3.05 (1H, dd, J = 16.0 Hz J = 5.2 Hz), 2.90 (1H, td, J = 13.2 Hz J = 3.2 Hz), 2.01 
(1H, br. d, J = 10.0 Hz), 1.93 – 1.91 (2H, m), 1.67 – 1.48 (3H, m). 13C NMR (CDCl3, 100 MHz): δ 
= 168.2, 160.2, 150.2, 149.0, 135.1, 133.9, 127.2, 126.4, 125.2, 123.4, 120.3, 116.1, 109.5, 105.1, 
103.7, 56.63, 56.52, 56.19, 53.54, 43.48, 36.65, 33.37, 25.39, 23.64. EI-MS: 391 [M].  
 
3,6,7-Trimethoxy-11,12,13,14,14a,15-hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinoline, 
Rac-boehmeriasin A (1, path A). To a solution of 3,6,7-trimethoxy-12,13,14,14a-tetrahydro-9H-
dibenzo[f,h]pyrido[1,2-b]isoquinolin-15(11H)-one (10) (391 mg, 1.0 mmol) in THF (5 mL, cooled 
to 0 °C) LiAlH4 (100 mg, 2.6 mmol) was added portionwise. After 10 min the mixture was allowed 
to warm to rt where it was stirred for 2 h, prior to careful quenching by addition of aqueous NH4Cl 
solution. After aqueous extraction with DCM the combined organic layers were dried over 
anhydrous Na2SO4 and evaporated under reduced pressure to give the intermediate aminoalcohol 
product as yellow oil which was not purified further. This crude material was redissolved in DCM 
(2 mL) and combined with TFA (0.3 mL) and Et3SiH (0.3 mL). After stirring for 4 h at 40 
o
C the 
reaction had reached completion (monitored by LC-MS) and was quenched by addition of aqueous 
NaHCO3 solution. The crude product was isolated after aqueous extraction as yellow foam. Final 
purification was accomplished by flash column chromatography furnishing racemic boehmeriasin A 
(1) as solid (308 mg, 82%) after evaporation of the solvents. IR (neat) ν 2931.1 (m), 1610.4 (m), 
1511.5 (s), 1467.9 (s), 1253.9 (s), 1201.9 (s), 1138.6 (s), 1038.7 (s), 837.8 (m), 783.1 (m), 728.9 (s) 
cm-1. LR-MS (ESI): 377.9 (M+H). HR-MS: calculated for C24H28O3N 378.2069, found 378.2055 
(Δ -3.7 ppm). 
HPLC: (AD 5 cm, EtOH: Hexane 9:1, 1 ml/min, 22 °C) can be used in order to achieve resolution 
of racemic boehmeriasin A (see Supporting Information).  
 
3,6,7-Trimethoxy-11,12,13,14,14a,15-hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinoline, 
boehmeriasin A (1, path B). To a cooled at 0 ºC suspension of LiAlH4 (0.020 g, 0.49 mmol) in 
THF (5 mL), a solution of compound 17 (48 mg, 0.12 mmol) in THF (2.5 mL) was added dropwise 
and the new mixture was refluxed for 2 h. After the completion of the reaction, the reaction mixture 
was cooled at 0 ºC, and carefully quenched by addition of 10% NaOH aqueous solution and after 
the THF was evaporated in vacuum. Then, the aqueous layer was extracted 3 times with EtOAc. 
The combined organic layers were washed with water and brine, dried with Na2SO4, filtered and 
evaporated. The residue was purified by flash column chromatography (DCM/MeOH 9.6:0.4) to 
provide boehmeriasin A (1) as solid. Yield 80%; Rf = 0.24 (DCM/MeOH, 9.6:0.4); 1a:  = – 
79.2 (c = 0.12 in MeOH), HR-MS: calculated for C24H28O3N 378.2069, found 378.2057. Anal. 
Calcd for C24H27NO3: C, 76.36; H, 7.21; N, 3.71. Found: C, 75.58; H, 7.02; N, 3.56; 1b:  = + 
80.6 (c = 0.10 in MeOH), HR-MS: found 378.2058; Found: C, 75.53; H, 7.04; N, 3.53. 
1
H NMR 
(CDCl3, 400 MHz): δ = 7.92 – 7.90 (3H, m), 7.22 (1H, dd, J = 8.8 Hz J = 2.4 Hz), 7.14 (1H, s), 4.64 
(1H, d, J = 15.2 Hz), 4.12 (3H, s), 4.07 (3H, s), 4.03 (3H, s), 3.58 (1H, d, J = 15.2 Hz), 3.30 (1H, d, 
J = 11.2 Hz), 3.18 (1H, dd, J = 16.4 Hz J = 2.8 Hz), 2.94 (1H, dd, J = 16.4 Hz J = 6.0 Hz), 2.41 – 
2.29 (2H, m), 2.03 (1H, d, J = 13.2 Hz), 1.92 – 1.78 (3H, m), 1.56 – 1.45 (2H, m). 13C NMR 
(CDCl3, 100 MHz): δ = 158.2, 150.1, 148.9, 130.9, 126.6, 125.9, 125.7, 124.9, 123.9, 115.4, 105.3, 
104.7, 103.8, 58.19, 57.05, 56.84, 56.66, 56.19, 35.35, 34.44, 26.67, 25.05.  
 
 
 
Virtual Screening 
(R)- and (S)-boehmeriasin A were used as input structures for Hurakan running the jobs on default 
parameters. 
 
Biological Evaluation. 
 
Cell proliferation: Endothelial cells. Bovine aortic endothelial cells (BAEC) and human dermal 
microvascular endothelial cells (HMEC-1) were seeded in 48-well plates at 10,000 cells/well and 
20,000 cells/well, respectively. After 24 h, 5-fold dilutions of the compounds were added. The cells 
were allowed to proliferate 3 days (or 4 days for HMEC-1) in the presence of the compounds, 
trypsinized, and counted by means of a Coulter counter (Analis, Belgium). Tumor cells. Human 
cervical carcinoma (HeLa) cells were seeded in 96-well plates at 15,000 cells/well in the presence 
of different concentrations of the compounds. After 4 days of incubation, the cells were trypsinized 
and counted in a Coulter counter. Suspension cells (Mouse leukemia L1210 and human lymphoid 
Cem cells) were seeded in 96-well plates at 60,000 cells/well in the presence of different 
concentrations of the compounds. L1210 and Cem cells were allowed to proliferate for 48 h or 96 h, 
respectively and then counted in a Coulter counter. The 50% inhibitory concentration (IC50) was 
defined as the compound concentration required to reduce cell proliferation by 50%. Combretastatin 
A-4 phosphate was added as reference compound. 
 
Analysis of in vitro sirtuin inhibition. SIRT1 and SIRT2 in Vitro Assay. The compounds were 
studied using the Fluor de Lys fluorescence assays which are described in the BioMol product sheet 
(Enzo Life Sciences). In assays the BioMol KI177 substrate was used for SIRT1 and the KI179 
substrate for SIRT2. The determined Km value of SIRT1 for KI177 was 58 µM and the Km of 
SIRT2 for KI179 was 198 µM.
32
 The Km values of SIRT1 and SIRT2 were 558 µM and 547µM for 
NAD+ reported by BioMol, respectively. 
Briefly, assays were carried out using the Fluor de Lys acetylated peptide substrate at 0.7 Km and 
NAD+ (Sigma N6522 or BioMol KI282) at 0.9 Km, recombinant GST-SIRT1/2-enzyme and SIRT 
assay buffer (KI286). GST-SIRT1 and GST-SIRT2 were produced as described previously. 
33, 34
 
The buffer together with Fluor de Lys acetylated peptide substrate, NAD+ and DMSO/compounds 
in DMSO (2.5 µL in 50 µL total reaction volume; DMSO from Sigma, D2650) were preincubated 
for 5 min at room temperature. Then enzyme was added to start the reaction. The reaction mixture 
was incubated for one hour at 37 °C and after that, Fluor de Lys developer (KI176) and 2 mM 
nicotinamide (KI283) in SIRT assay buffer (total volume 50 µL) were added. The incubation was 
continued for 45 min at 37 °C. Finally, fluorescence readings were obtained using EnVision 2104 
Multilabel Reader (PerkinElmer) with excitation wavelength 370 nm and emission 460 nm. 
 
Topoisomerase-Mediated DNA Relaxation. Supercoiled pBR322 plasmid DNA (0.25 µg, 
Fermentas Life Sciences) was incubated with 1U topoisomerase II (human recombinant 
topoisomerase II , USB Corporation) or 2U topoisomerase I (human recombinant topoisomerase I, 
TopoGen) and the test compounds as indicated, for 60 min at 37 °C in 20 L reaction buffer. 
Reactions were stopped by adding 4 µL stop buffer (5% sodium dodecyl sulfate (SDS), 0.125% 
bromophenol blue, and 25% glycerol), 50 µg/mL proteinase K (Sigma) and incubating for a further 
30 min at 37 °C. The samples were separated by electrophoresis on a 1% agarose gel at room 
temperature. The gels were stained with ethidium bromide 1 µg/mL in TAE buffer (0.04 M Tris-
acetate and 0.001 M EDTA), transilluminated by UV light, and fluorescence emission was 
visualized by a CCD camera coupled to a Bio-Rad Gel Doc XR apparatus. 
 
Topoisomerase II-mediated DNA cleavage. Reaction mixtures (20 L) containing 10 mM Tris-
HCl (pH=7.9), 50 mM NaCl, 50 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 15 g/mL bovine serum 
albumin, 1 mM ATP, 0.25 g pBR322 plasmid DNA (Fermentas Life Sciences), 10 U 
topoisomerase II (human recombinant topoisomerase II , USB Corporation) and test compounds 
were incubated for 60 min at 37 °C. Reactions were stopped by adding 4 L stop buffer (5% SDS, 
0.125% bromophenol blue and 25% glycerol), 50 g/mL proteinase K (Sigma) and incubating for a 
further 30 min at 37 °C. The samples were separated by electrophoresis on a 1% agarose gel 
containing ethidium bromide 0.5 g/mL at room temperature in TBE buffer (0.09 M Tris-borate 
and 0.002 M EDTA), transilluminated by UV light, and fluorescence emission was visualized by a 
CCD camera coupled to a Bio-Rad Gel Doc XR apparatus.  
 
Topoisomerase I-mediated DNA cleavage. Reaction mixtures (20 μL) containing 35 mM Tris-
HCl (pH=8.0), 72 mM KCl, 5 mM MgCl2, 5 mM DTT, 5 mM spermidine, 0.01% bovine serum 
albumin , 20 ng pBR322 plasmid DNA (Fermentas Life Sciences), 5 U topoisomerase I (human 
recombinant topoisomerase I, TopoGen) and test compounds were incubated for 60 min at 37°C. 
Reactions were stopped by adding 4 μL of stop buffer (5% SDS, 0.125% bromophenol blue and 
25% glycerol), 50 g/mL proteinase K (Sigma)  and incubating for a further 30 min at 37°C. The 
samples were separated by electrophoresis on a 1% agarose gel containing ethidium bromide 0.5 
μg/mL (Sigma) at room temperature in TBE buffer (0.09 M Tris-borate and 0.002 M EDTA), 
transilluminated by UV light, and fluorescence emission was visualized by a CCD camera coupled 
to a Bio-Rad Gel Doc XR apparatus.  
 
Docking Studies. 
Topoisomerase: (R)- and (S)-Boehmeriasin A were docked in the enzyme mediated DNA cleavage 
site in the crystal structure of the topoisomerase I and of the topoisomerase II-beta, both in complex 
with DNA (PDB id  1T8I and 4G0U respectively) 
35, 36 
using AutoDock 4.2 software.
37
 All 
crystallographic water molecules were removed as well as the cocrystallized ligands. A 60x60x60 
grid of points in the x, y and z direction respectively was built centered on the center of mass of the 
removed ligand; a grid spacing of 0.375 Å was used. A Lamarkian genetic algorithm
38
 was 
employed for the docking  simulation, performing 100 independent runs per molecule. In each run, 
a population of 50 individuals evolved along 27000 generations and a maximum number of 25 
million energy evaluations were performed. The best fit (lowest docked energy) solutions of the 100 
independent runs for were stored for subsequent analysis. Cluster analysis was performed on the 
results using an RMSD tolerance of 2.0 Å. 
Sirtuins: (R)- and (S)-Boehmeriasin A were docked in the crysral structure of SIRT1 complex with 
Ex-527(PDB id 4I5I)
39
 and the homology model of SIRT2
40
 using Schrödinger’s Glide software.41 
The protein structure was preprocessed with Protein Preparation Wizard of Schrödinger Maestro 
using standard settings (add hydrogens, assign bond orders, create zero order bonds to metals and 
disulfide bonds and delete waters beyond 5 Å from heteroatoms), the hydrogen bonds were 
assigned and the prepared structure was minimized using OPLS_2005 force field and restrained 
minimization (heavy atom converging RMSD 0.30 Å). The Glide grid was constructed for ligands < 
20 Å in length and the center of the grid was defined into the place of the nicotinamide-moiety (so 
called C-pocket) for SIRT1 based on co-crystallized ligand, EX-527. For SIRT2 the center of the 
grid was defined based on the residues Ile93, Ile169 and Phe119 (residue numbering in SIRT2). 
Several docking runs were performed and the best scored results were visually inspected. 
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